Archives of Pharmacal Research

, Volume 39, Issue 2, pp 240–248 | Cite as

Resveratrol attenuates norepinephrine-induced ovarian cancer invasiveness through downregulating hTERT expression

  • Seung Hwa Kim
  • Kyung Hwa Cho
  • Yu Na Kim
  • Bo Young Jeong
  • Chang Gyo Park
  • Gang Min Hur
  • Hoi Young Lee
Research Article

Abstract

Stress hormone norepinephrine (NE) has been associated with acquisition of cancer progression, and naturally occurring phytoalexin resveratrol (REV) has been known to suppress cancer growth and progression. In the present study, we determine the effect of REV on NE-induced ovarian cancer invasiveness. Pretreatment of REV significantly inhibited NE-induced ovarian cancer cell epithelial-to-mesenchymal transition with concomitant recovery of E-cadherin expression. In addition, our data showed that REV downregulates NE-induced human telomerase reverse transcriptase (hTERT) expression through inhibiting Src phosphorylation and HIF-1α expression. Further, REV reduced NE-induced Slug expression and subsequent ovarian cancer invasion. More importantly, combined treatment of REV with a pharmacological inhibitor of beta adrenergic receptor significantly attenuated NE-induced ovarian cancer invasion compared to single treatment. Therefore, we demonstrate interference of a Src and HIF-1α/hTERT/Slug signaling cascade by REV, providing potential therapeutic targets and inhibition of ovarian cancer.

Keywords

Resveratrol Telomerase Ovarian cancer Metastasis 

References

  1. Armaiz-Pena, G.N., J.K. Allen, A. Cruz, R.L. Stone, A.M. Nick, Y.G. Lin, L.Y. Han, L.S. Mangala, G.J. Villares, P. Vivas-Mejia, C. Rodriguez-Aguayo, A.S. Nagaraja, K.M. Gharpure, Z. Wu, R.D. English, K.V. Soman, M.M. Shazhad, M. Zigler, M.T. Deavers, A. Zien, T.G. Soldatos, D.B. Jackson, J.E. Wiktorowicz, M. Torres-Lugo, T. Young, K. De Geest, G.E. Gallick, M. Bar-Eli, G. Lopez-Berestein, S.W. Cole, G.E. Lopez, S.K. Lutgendorf, and A.K. Sood. 2013. Src activation by beta-adrenoreceptors is a key switch for tumour metastasis. Nature Communications 4: 1403.PubMedCentralCrossRefPubMedGoogle Scholar
  2. Baribeau, S., P. Chaudhry, S. Parent, and E. Asselin. 2014. Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. PLoS One 9: e86987.PubMedCentralCrossRefPubMedGoogle Scholar
  3. Choi, M.J., K.H. Cho, S. Lee, Y.J. Bae, K.J. Jeong, S.Y. Rha, E.J. Choi, J.H. Park, J.M. Kim, J.S. Lee, G.B. Mills, and H.Y. Lee. 2015. hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness. Oncogene 34: 3402–3412.CrossRefPubMedGoogle Scholar
  4. De Craene, B., B. Gilbert, C. Stove, E. Bruyneel, F. van Roy, and G. Berx. 2005. The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Research 65: 6237–6244.CrossRefPubMedGoogle Scholar
  5. Gallo, D., C. Ferlini, and G. Scambia. 2010. The epithelial-mesenchymal transition and the estrogen-signaling in ovarian cancer. Current Drug Targets 11: 474–481.CrossRefPubMedGoogle Scholar
  6. Gardner, M.J., L.M. Jones, J.B. Catterall, and G.A. Turner. 1995. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Letters 91: 229–234.CrossRefPubMedGoogle Scholar
  7. Hajra, K.M., D.Y. Chen, and E.R. Fearon. 2002. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Research 62: 1613–1618.PubMedGoogle Scholar
  8. Hassan, S., Y. Karpova, D. Baiz, D. Yancey, A. Pullikuth, A. Flores, T. Register, J.M. Cline, R. D’Agostino Jr, N. Danial, S.R. Datta, and G. Kulik. 2013. Behavioral stress accelerates prostate cancer development in mice. The Journal of Clinical Investigation 123: 874–886.PubMedCentralPubMedGoogle Scholar
  9. Hu, F.W., L.L. Tsai, C.H. Yu, P.N. Chen, M.Y. Chou, and C.C. Yu. 2012. Impairment of tumor-initiating stem-like property and reversal of epithelial-mesenchymal transdifferentiation in head and neck cancer by resveratrol treatment. Molecular Nutrition & Food Research 56: 1247–1258.CrossRefGoogle Scholar
  10. Jang, M., L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W. Beecher, H.H. Fong, N.R. Farnsworth, A.D. Kinghorn, R.G. Mehta, R.C. Moon, and J.M. Pezzuto. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218–220.CrossRefPubMedGoogle Scholar
  11. Jeong, K.J., S.Y. Park, K.H. Cho, J.S. Sohn, J. Lee, Y.K. Kim, J. Kang, C.G. Park, J.W. Han, and H.Y. Lee. 2012. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 31: 4279–4289.CrossRefPubMedGoogle Scholar
  12. Kotha, A., M. Sekharam, L. Cilenti, K. Siddiquee, A. Khaled, A.S. Zervos, B. Carter, J. Turkson, and R. Jove. 2006. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Molecular Cancer Therapeutics 5: 621–629.CrossRefPubMedGoogle Scholar
  13. Lang, K., T.L. Drell, A. Lindecke, B. Niggemann, C. Kaltschmidt, K.S. Zaenker, and F. Entschladen. 2004. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. International Journal of Cancer 112: 231–238.CrossRefGoogle Scholar
  14. Lanzilli, G., M.P. Fuggetta, M. Tricarico, A. Cottarelli, A. Serafino, R. Falchetti, G. Ravagnan, M. Turriziani, R. Adamo, O. Franzese, and E. Bonmassar. 2006. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. International Journal of Oncology 28: 641–648.PubMedGoogle Scholar
  15. Lara, H.E., A. Porcile, J. Espinoza, C. Romero, S.M. Luza, J. Fuhrer, C. Miranda, and L. Roblero. 2001. Release of norepinephrine from human ovary: Coupling to steroidogenic response. Endocrine 15: 187–192.CrossRefPubMedGoogle Scholar
  16. Lara, H.E., M. Dorfman, M. Venegas, S.M. Luza, S.L. Luna, A. Mayerhofer, M.A. Guimaraes, E.S.A.A. Rosa, and V.D. Ramirez. 2002. Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: Studies on norepinephrine release. Microscopy Research and Technique 59: 495–502.CrossRefPubMedGoogle Scholar
  17. Liu, Z., Q. Li, K. Li, L. Chen, W. Li, M. Hou, T. Liu, J. Yang, C. Lindvall, M. Bjorkholm, J. Jia, and D. Xu. 2012. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 32: 4203–4213.CrossRefPubMedGoogle Scholar
  18. Lutgendorf, S.K., S. Cole, E. Costanzo, S. Bradley, J. Coffin, S. Jabbari, K. Rainwater, J.M. Ritchie, M. Yang, and A.K. Sood. 2003. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clinical Cancer Research 9: 4514–4521.PubMedGoogle Scholar
  19. McEwen, B.S. 2002. Sex, stress and the hippocampus: Allostasis, allostatic load and the aging process. Neurobiology of Aging 23: 921–939.CrossRefPubMedGoogle Scholar
  20. Nilsson, M.B., G. Armaiz-Pena, R. Takahashi, Y.G. Lin, J. Trevino, Y. Li, N. Jennings, J. Arevalo, S.K. Lutgendorf, G.E. Gallick, A.M. Sanguino, G. Lopez-Berestein, S.W. Cole, and A.K. Sood. 2007. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. Journal of Biological Chemistry 282: 29919–29926.CrossRefPubMedGoogle Scholar
  21. Ozols, R.F., M.A. Bookman, D.C. Connolly, M.B. Daly, A.K. Godwin, R.J. Schilder, X. Xu, and T.C. Hamilton. 2004. Focus on epithelial ovarian cancer. Cancer Cell 5: 19–24.CrossRefPubMedGoogle Scholar
  22. Palm, D., K. Lang, B. Niggemann, T.L. Drell, K. Masur, K.S. Zaenker, and F. Entschladen. 2006. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. International Journal of Cancer 118: 2744–2749.CrossRefGoogle Scholar
  23. Park, S.Y., K.J. Jeong, J. Lee, D.S. Yoon, W.S. Choi, Y.K. Kim, J.W. Han, Y.M. Kim, B.K. Kim, and H.Y. Lee. 2007. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: Their inhibition by resveratrol. Cancer Letters 258: 63–69.CrossRefPubMedGoogle Scholar
  24. Park, S.Y., J.H. Kang, K.J. Jeong, J. Lee, J.W. Han, W.S. Choi, Y.K. Kim, J. Kang, C.G. Park, and H.Y. Lee. 2011. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. International Journal of Cancer 128: 2306–2316.CrossRefGoogle Scholar
  25. Shahzad, M.M., J.M. Arevalo, G.N. Armaiz-Pena, C. Lu, R.L. Stone, M. Moreno-Smith, M. Nishimura, J.W. Lee, N.B. Jennings, J. Bottsford-Miller, P. Vivas-Mejia, S.K. Lutgendorf, G. Lopez-Berestein, M. Bar-Eli, S.W. Cole, and A.K. Sood. 2010. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. Journal of Biological Chemistry 285: 35462–35470.PubMedCentralCrossRefPubMedGoogle Scholar
  26. Siegel, R., C. Desantis, K. Virgo, K. Stein, A. Mariotto, T. Smith, D. Cooper, T. Gansler, C. Lerro, S. Fedewa, C. Lin, C. Leach, R.S. Cannady, H. Cho, S. Scoppa, M. Hachey, R. Kirch, A. Jemal, and E. Ward. 2012. Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians 62: 220–241.Google Scholar
  27. Sood, A.K., R. Bhatty, A.A. Kamat, C.N. Landen, L. Han, P.H. Thaker, Y. Li, D.M. Gershenson, S. Lutgendorf, and S.W. Cole. 2006. Stress hormone-mediated invasion of ovarian cancer cells. Clinical Cancer Research 12: 369–375.PubMedCentralCrossRefPubMedGoogle Scholar
  28. Thaker, P.H., L.Y. Han, A.A. Kamat, J.M. Arevalo, R. Takahashi, C. Lu, N.B. Jennings, G. Armaiz-Pena, J.A. Bankson, M. Ravoori, W.M. Merritt, Y.G. Lin, L.S. Mangala, T.J. Kim, R.L. Coleman, C.N. Landen, Y. Li, E. Felix, A.M. Sanguino, R.A. Newman, M. Lloyd, D.M. Gershenson, V. Kundra, G. Lopez-Berestein, S.K. Lutgendorf, S.W. Cole, and A.K. Sood. 2006. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine 12: 939–944.CrossRefPubMedGoogle Scholar
  29. Vergara, D., C.M. Valente, A. Tinelli, C. Siciliano, V. Lorusso, R. Acierno, G. Giovinazzo, A. Santino, C. Storelli, and M. Maffia. 2011. Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Letters 310: 1–8.CrossRefPubMedGoogle Scholar
  30. Wang, H., H. Zhang, L. Tang, H. Chen, C. Wu, M. Zhao, Y. Yang, X. Chen, and G. Liu. 2013. Resveratrol inhibits TGF-beta1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis. Toxicology 303: 139–146.CrossRefPubMedGoogle Scholar
  31. Xia, L., X.X. Wang, X.S. Hu, X.G. Guo, Y.P. Shang, H.J. Chen, C.L. Zeng, F.R. Zhang, and J.Z. Chen. 2008. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. British Journal of Pharmacology 155: 387–394.PubMedCentralCrossRefPubMedGoogle Scholar
  32. Yang, J., S.A. Mani, J.L. Donaher, S. Ramaswamy, R.A. Itzykson, C. Come, P. Savagner, I. Gitelman, A. Richardson, and R.A. Weinberg. 2004. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927–939.CrossRefPubMedGoogle Scholar
  33. Zhang, Q., X. Tang, Q.Y. Lu, Z.F. Zhang, J. Brown, and A.D. Le. 2005. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Molecular Cancer Therapeutics 4: 1465–1474.CrossRefPubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2015

Authors and Affiliations

  • Seung Hwa Kim
    • 1
  • Kyung Hwa Cho
    • 1
  • Yu Na Kim
    • 1
  • Bo Young Jeong
    • 1
  • Chang Gyo Park
    • 1
  • Gang Min Hur
    • 2
  • Hoi Young Lee
    • 1
  1. 1.Department of Pharmacology, College of MedicineKonyang UniversityDaejeonRepublic of Korea
  2. 2.Department of Pharmacology, Daejeon Regional Cancer Center, College of MedicineChungnam National UniversityDaejeonRepublic of Korea

Personalised recommendations